Reported 2 days ago
J.P. Morgan analyst Jessica Fye reaffirmed a Buy rating for Legend Biotech Corporation (LEGN) on October 9, setting a price target of $76, citing the company's strong growth potential despite current supply constraints with its Carvykti product. TD Cowen also maintained a Buy rating with a target of $62, highlighting the company's strategic positioning and expectations to meet a $1.9 billion sales target for fiscal year 2025. Legend Biotech specializes in innovative therapies for oncology and operates in multiple regions, including the U.S. and China.
Source: YAHOO